Conditions: Opiate Dependence Depression
Keywords: opiate use depression buprenorphine escitalopram
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 147
Healthy volunteers: yes

Brief summary:
This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Detailed description:
Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: escitalopram intervention 2: placebo
Intervention descriptions: intervention 1: 10mg escitalopram/day for 3 months intervention 2: placebo capsule/day for 3 months

Protocol document: